Project Grant R61NS135019
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$429K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This $128,286 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to determine the DNA repair defects caused by mutations in the XPD gene and provide mechanistic insights into the genetic disorders Xeroderma Pigmentosum (XP) and Xeroderma Pigmentosum combined with Cockayne Syndrome (XP/CS). The award, made on January 15, 2025, will fund a multi-disciplinary research project...
This $1,369,242 project grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS, CFDA 93.853) aims to develop an adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis (MPS) IIIB, a rare lysosomal storage disease. The project focuses on optimizing and scaling up the manufacturing of the AAV9-based gene therapy product containing a codon-optimized human NAGLU cDNA. Phase I activities will involve engineering trials to develop and...
This $1,009,212 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research into a novel gene therapy approach to reduce neurotoxicity in Parkinson's disease. The primary awardee, Van Andel Research Institute (VAI), will conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to develop a gene therapy that aims to enhance the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $349,909 to Neurogt Inc. to develop an adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis Type IIIC (MPS IIIC), a rare lysosomal storage disease that currently lacks an effective treatment. The key objectives are to further advance a novel AAV9-based gene...
This $367,059 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop a better understanding of the genomic, epigenomic, and transcriptomic outcomes of gene therapy. The research will explore key questions around the long-term effects of vector integration, the role of cell/tissue type and promoters, and differential host responses to various gene therapy delivery vehicles. The...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $395,009 to the University of California, Davis to lay the foundation for developing a molecular therapy for ADNP syndrome. The key products and services to be delivered under this 2-year award include: Testing the presumed mechanism of action of antisense oligonucleotides (ASOs) that can...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $420,771 to the Regents of the University of Minnesota to develop a targeted genetic therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). The project aims to use adenosine base editing and CRISPR gene editing to restore function to the Artemis gene in hematopoietic stem cells, both ex vivo...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $803,958 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant funding supports the development of an innovative nanocarrier drug delivery system to enable stable and sustained delivery of a novel enzyme therapy to the brain for the treatment of neuronopathic Gaucher disease....
This $2,696,128 federal Project Grant award, funded under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports preclinical development of a gene replacement therapy using novel adeno-associated virus (AAV) vectors to treat familial cerebral cavernous malformations (CCM). The prime awardee is Duke University, which is collaborating with the University of Chicago as a sub-awardee. Duke's work focuses on developing the gene therapy treatment, while...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support preclinical testing of a novel gene therapy for a rare pediatric neurodegenerative disease. The $419,482 award to the University of Texas Southwestern Medical Center will fund studies to determine the minimal effective dose and post-symptomatic treatment efficacy of the...